Lung Cancer Clinical Trial

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.

View Full Description

Full Description

OBJECTIVES:

Primary Objective:

Determine the efficacy of selenium in terms of reducing the incidence of second primary lung tumors in participants with previously resected stage I non-small cell lung cancer.

Secondary Objectives:

Evaluate the qualitative and quantitative toxicity of selenium in these patients.
Compare the incidence of specific cancers, mortality from cancer, and overall survival of participants treated with selenium vs those treated with placebo.

OUTLINE: This is a randomized, double-blinded, placebo-controlled, multicenter study. Participants are stratified according to smoking status (actively smoking or stopped less than 1 year ago vs. stopped at least 1 year ago vs. never smoked or no more than 100 cigarettes ever), gender, and stage and previous therapy (stage IA vs. stage IB with previous therapy vs. stage IB with no previous therapy). Participants are randomized in a 1:2 ratio to arm I and arm II.

Arm I: Participants receive an oral yeast placebo as in arm II.
Arm II: Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.

Participants are followed annually (every 12 months) for 10 years.

PROJECTED ACCRUAL: A total of 1,960 participants will be accrued for this study within 4 years.

View Eligibility Criteria

Eligibility Criteria

RUN-IN PERIOD:

Inclusion Criteria:

Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small lung cancer (except carcinoid)*

Completion of treatment for stage I lung cancer within the past 6 to 36 months and currently disease free
At least one mediastinal lymph node sampled at resection NOTE: *Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B (CALGB) patients must be T1, N0; CALGB patients may be T2, N0 provided disease was completely resected prior to June 1, 2001 and participation in CALGB 9633 was refused if offered
18 years old and over
Eastern Cooperative Oncology Group performance status 0-1
Bilirubin no greater than upper limit of normal (ULN)
Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) no greater than ULN
Prior mineral, herbal, phytochemical, or vitamin supplementation allowed
Concurrent non-selenium containing mineral, herbal, phytochemical, or vitamin supplementation allowed if schedule and supplementation prior to study remains unchanged

Exclusion Criteria:

Evidence of new or recurrent lung cancer on chest x-ray within the past 8 weeks
Synchronous lung or non-lung lesions or metastasis, even if resectable
History of more than one primary lung cancer at any time
Concurrent or other prior cancer within the past 5 years except localized non-melanoma skin cancer
Prior or concurrent chemotherapy for recurrent lung cancer
Prior or concurrent radiotherapy for recurrent lung cancer
Concurrent surgery
Concurrent supplement(s) containing more than 50 micrograms of selenium

STUDY PHASE:

Free of disease
Consumed at least 75% of tablets during 4-week run-in period

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

1772

Study ID:

NCT00008385

Recruitment Status:

Completed

Sponsor:

ECOG-ACRIN Cancer Research Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 440 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

1772

Study ID:

NCT00008385

Recruitment Status:

Completed

Sponsor:


ECOG-ACRIN Cancer Research Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.